3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
121
Lymphoma, Mantle-Cell
68
Lymphoma, Large B-Cell, Diffuse
40
Lymphoma, Non-Hodgkin
31
Lymphoma, Follicular
30
Waldenstrom Macroglobulinemia
29
Lymphoma
29
Recurrence
22
Lymphoma, B-Cell
22
Lymphoma, B-Cell, Marginal Zone
19
Neoplasms
14
Leukemia
13
Leukemia, B-Cell
10
Burkitt Lymphoma
8
Leukemia, Lymphoid
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Hodgkin Disease
5
Leukemia, Prolymphocytic
4
Bronchiolitis Obliterans Syndrome
4
Multiple Myeloma
3
Lymphoproliferative Disorders
3
Lymphatic Diseases
3
Leukemia, Myeloid, Acute
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hematologic Neoplasms
3
Hematologic Diseases
3
Chromosome 17 deletion
3
Leukemia, Prolymphocytic, B-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Interventions
blinatumomab
16
Cyclophosphamide
15
fludarabine phosphate
8
fludarabine
8
Methotrexate
7
Cytarabine
7
Rituximab
6
Vincristine
5
Mercaptopurine
5
Melphalan
4
Daunorubicin
4
obinutuzumab
3
Whole-Body Irradiation
3
Immunotherapy, Adoptive
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Doxorubicin
3
Dexamethasone
3
Asparaginase
3
tisagenlecleucel
2
thymoglobulin
2
pegaspargase
2
Vindesine
2
Thioguanine
2
Teniposide
2
Stem Cell Transplantation
2
Radiotherapy
2
Prednisone
2
Prednisolone
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
ibrutinib
×
Lymphoid
×
Clear all
NCT02666898
2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2
Completed
135 enrolled